RNA Outsourcing Resources

  1. Phase-Appropriate Approaches To Manufacturing And Testing 3/14/2025

    Accelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.

  2. Reducing Costs & Risks: A Pharma Guide To FTZ Subzones For U.S. Drug Manufacturing 2/11/2025

    Utilized wisely, FTZs and subzones can be tools for cost savings and can enable pharma companies to leverage the benefits of American manufacturing.

  3. Addressing And Adapting To Evolving mRNA Market Trends 7/6/2022

    Pierre Catignol and Huisub Lim share their insights on current mRNA market trends, manufacturability, choosing an appropriate CDMO partner, and mRNA technology considerations.

  4. How Operational Efficiency Shapes Late-Phase Manufacturability 6/26/2026

    Prioritize operational efficiency over early-stage flexibility to scale advanced therapies. Standardized workflows and qualified shipping lanes reduce variability for predictable late-phase success.

  5. Supercharge Your Supply Chain: Harness AI To Gain Competitive Advantage

    The success of CGTs hinges upon adherence to specific logistics protocols. Learn how the integration of AI in the pharma supply chain is poised to enhance visibility, efficiency, and compliance.

  6. Four Reasons You Should Choose Lyophilization for Your Next Project 12/10/2025

    Lyophilization ensures product stability, extends shelf life, supports sensitive formulations, and simplifies storage and transport, making it a critical choice for modern drug development projects.

  7. Choosing The Best mRNA Manufacturing Strategy 12/12/2025

    Choosing the right mRNA manufacturing model can define your success. Learn how to weigh control, cost, and flexibility to build a strategy that supports innovation and long-term growth.

  8. Driving Compliance And Standardization In CGT Supply Chains 12/29/2025

    Standardization and compliance in CGT supply chains are critical for minimizing risk, ensuring product integrity, and meeting regulatory demands across global manufacturing and distribution networks.

  9. The Critical Bottleneck In Personalized Cancer Vaccines 6/19/2026

    Personalized cancer vaccines face a DNA production bottleneck. Synthetic approaches speed timelines, boost consistency, and simplify workflows to deliver individualized therapies faster.

  10. What's Next For ATMP Regulation In EMEA 10/20/2025

    Fragmented national regulations for pricing, customs, and reimbursement demand tailored supply chain strategies. Adapting to country-specific hurdles is essential for product integrity and patient access.